Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE–AF Randomized Clinical Trial

JAMA Cardiology
Subanalysis (n=984) found among Japanese patients age ≥80 years not suitable for standard dose DOACs, 15mg OD dose of edoxaban was superior to placebo in preventing stroke/systemic embolism, albeit with numerically, but non-statistically significantly, higher incidence of bleeding.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services